Butadion, tablets 150 mg 20 pcs

Pharmgroup:

NSAIDs.

Pharm Action:

PNP, has anti-inflammatory, analgesic and antipyretic effects associated with inhibition of COX activity, and COX2, regulating the synthesis of PG. Exhibits uricosuric action.

Pharmacokinetics:

In oral administration absorption – high; bioavailability – 85-90%, reduced with prolonged administration. TCmax – 1-2 hours. Binding to plasma proteins – more than 95%.

It is metabolized in the liver with the formation of 2 main metabolites. T1/2 – 18-24 hours. It is excreted by the kidneys 70% (5% unchanged), through the gastrointestinal tract – 30% as metabolites, a significant amount is excreted with the breast milk.

Indications

I and II degree burns of a small area, including sunburn; dermatitis, skin inflammation at the site of intramuscular or intravenous injections, insect bites; inflammation of hemorrhoids and superficial thrombophlebitis; traumatic injuries of soft tissues; ankylosing spondylitis, erythema nodosum, chorea minor, etc.

Butadione is used for the treatment of joint diseases of various etiologies – acute and subacute stages of articular rheumatism (inferior, however, to salicylates for heart defects complicated by endomyocarditis and circulatory disorders), acute, subacute and chronic rheumatoid polyarthritis, nonspecific infectious polyarthritis, gout, thrombophlebitis, osteoarthritis, tendonitis, Tenosynovitis.

The beneficial effect of Butadione is observed in bronchial asthma, neuralgia, neuritis, myalgia.

Pharmacological effect

Pharmaceutical group:

NSAIDs.

Pharmaceutical action:

NSAIDs have anti-inflammatory, analgesic and antipyretic effects associated with the suppression of the activity of COX and COX2, which regulate the synthesis of PG. Shows uricosuric effect.

Pharmacokinetics:

When taken orally, absorption is high; bioavailability – 85-90%, decreases with long-term use. TCmax – 1-2 hours. Communication with plasma proteins – more than 95%.

Metabolized in the liver to form 2 main metabolites. T1/2 – 18-24 hours. 70% is excreted by the kidneys (5% unchanged), through the gastrointestinal tract – 30% in the form of metabolites, and is excreted in significant quantities in breast milk.

Special instructions

During treatment, it is necessary to monitor the peripheral blood picture and the functional state of the liver and kidneys.
If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

During treatment, you should refrain from engaging in potentially hazardous activities that require increased attention and speed of mental and motor reactions. To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used for the shortest possible short course.

Active ingredient

Phenylbutazone

Composition

Phenylbutazone 150 mg.

Contraindications

Hypersensitivity; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to ASA or other NSAIDs (including a history);
erosive and ulcerative lesions of the gastrointestinal tract in the acute stage (gastric and duodenal ulcers, ulcerative colitis, peptic ulcers), bone marrow depression, decompensated CHF or pulmonary heart failure, severe liver and/or renal failure (creatinine clearance less than 30 ml/min), the period after coronary artery bypass grafting;
progressive kidney disease, active liver disease, confirmed hyperkalemia,
pregnancy (III trimester), active gastrointestinal bleeding, inflammatory bowel disease.
With caution. Hyperbilirubinemia, bronchial asthma, CHF, edema, arterial hypertension, hemophilia, hypocoagulation, liver failure, chronic renal failure, hearing loss, pathology of the vestibular apparatus, blood diseases, diabetes mellitus, SLE, polymyalgia rheumatica, transient arteritis, ulcerogenic gastrointestinal diseases, stomatitis, ischemic heart disease, cerebrovascular diseases, dyslipidemia/hyperlipidemia, peripheral arterial disease, smoking, chronic renal failure (creatinine clearance 30-60 ml/min), history of gastrointestinal ulcers, presence of H. pylori infection,
old age, long-term use of NSAIDs, alcoholism, severe somatic diseases, simultaneous use of oral corticosteroids (including prednisolone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline),
pregnancy, lactation period.

Side Effects

From the digestive system: dyspepsia, NSAID gastropathy, abdominal pain, nausea, vomiting, heartburn, diarrhea or constipation; with long-term use in large doses – ulceration of the gastrointestinal mucosa, aphthous stomatitis, glossitis, erosive esophagitis, bleeding (gastrointestinal, gingival, hemorrhoidal), liver dysfunction.

From the cardiovascular system: increased blood pressure, tachycardia.

From the nervous system: headache, dizziness, drowsiness, depression, agitation.

From the senses: hearing loss, tinnitus.

From the hematopoietic organs: agranulocytosis, leukopenia, anemia, thrombocytopenia.

Allergic reactions: skin rash, itching, urticaria, bronchospasm, edema syndrome, angioedema.

Other: increased sweating, uterine bleeding.

Interaction

Enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics, side effects of GCS and MCS, estrogens, morphine, PAS, penicillin, hypoglycemic effect of sulfonylurea derivatives.

Reduces the effectiveness of uricosuric, antihypertensive drugs and diuretics.

Increases the concentration of Li+ drugs and methotrexate in the blood.

Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) increase the production of hydroxylated active metabolites.

Antacids and cholestyramine reduce absorption.

Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

Overdose

Symptoms: cyanosis of the fingertips, lips, body skin, dizziness, headache, increased or decreased blood pressure, hyperventilation of the lungs, clouding of consciousness, in children – myoclonic convulsions, nausea, vomiting, abdominal pain, hemorrhages, impaired liver and kidney function.

Treatment: gastric lavage, administration of activated carbon, symptomatic therapy aimed at maintaining the vital functions of the body. Forced diuresis and hemodialysis are ineffective.

Manufacturer

Alium JSC, Russia